Wednesday, June 8, 2022 | 8.55 AM - 3.30 PM (EST)

8:55 am Chair’s Opening Remarks

9:00 am 2022 & Beyond: What’s the Current & Future State of the JAK Inhibitor Landscape


  • Outlining the successes of the past year in JAK inhibitor drug development
  • Reflecting on the JAK black box warning and the implications this may have on
    the industry moving forward
  • Highlighting the hot-pockets of innovation where we can expect JAK inhibitors
    to excel

Reviewing JAK Inhibitor Formulation & Drug Delivery Systems

9:30 am PANEL DISCUSSION – The Road Ahead: Topicals vs Orals vs Alternative Delivery Methods

  • Patrick Burnett Senior Vice President & Chief Medical Officer, Arcutis Therapeutics
  • Robert Clarke Chief Executive Officer & Co-Founder, Kinaset Therapeutics
  • Angela Christiano PhD Professor of Dermatology & Genetics, Columbia University
  • Raj Chovatiya Assistant Professor Director, Center for Eczema and Itch Department of Dermatology, Northwestern University Feinberg School of Medicine


  • Exploring the JAK inhibitor drug development landscape and weighing the merit of pursuing topical vs oral vs
    alternative application
  • Considering the cost concerns and systemic effects associated with oral and injectable delivery systems whilst
    discussing the small potential for off-target effects in topical creams
  • Discussing the need to equate disease severity and quality of life with safety concerns associated with JAK inhibition
  • Reflecting on the practicality of topical delivery as a long-term disease management strategy

10:15 am The Story of Ruxolitinib: The First Approved Topical JAK Inhibitor for Atopic Dermatitis

  • Jim Lee Head Immunology & Inflammation, Incyte


  • The story from discovery to clinical development for a moderate to severe
    inflammatory skin indication
  • Inspecting the JAK/STAT pathways critical to Incyte’s JAK inhibitor portfolio
  • Reviewing the commercialization and market strategy of a ‘twice daily’ applied
    topical cream

10:45 am
Morning Break & Structured Networking Session

11:15 am Overview of JAK Inhibitor Inhaled Formulation

  • Robert Clarke Chief Executive Officer & Co-Founder, Kinaset Therapeutics


  • Cataloguing autoimmune diseases where JAK inhalation may be sensible
  • Considering toxicity and potential for off-target effects with inhaled JAKs
  • Evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of
    a novel potent pan-JAK inhaled as a dry powder

11:45 am Repositioning a JAKi to Reduce Mortality in Patients with COVID-19


  • Rationalizing the use of a JAKi in COVID-19 patients
  • Reviewing the data from a phase 3 COVID-19 trial
  • Exploring other potential novel therapeutic targets for Baricitinib

12:15 pm
Lunch Break

Exploring JAK Selectivity in the Push Towards Precise Medical Approaches

1:15 pm Exploring the Potential for JAK1 Selectivity in Autoimmune Dermatological Conditions

  • Patrick Burnett Senior Vice President & Chief Medical Officer, Arcutis Therapeutics


  • Overcoming pre-clinical hurdles in dermatology to enable topical JAK inhibitor
  • Considering route of delivery and the implications on safety and efficacy
  • Preparing a JAK inhibitor pipeline for transition from pre-clinic to phase 1 trials

1:45 pm Overviewing the Alopecia Areata JAK Inhibitor Drug Development Landscape


  • Relaying the recent advances in JAK inhibitor trial approvals for alopecia to inform future pipeline decision making
  • Considerations to make when translating JAK inhibitors to the clinic

2:15 pm
Afternoon Break & Networking

2:45 pm Round-table Discussion: Improving Cross-functional Collaboration in Biopharma


  • Exploring current shortcomings within workplace collaboration
  • Brainstorming novel routes to elevating cross-functional relationships

3:30 pm END OF DAY ONE